Combined-modality treatment of locally advanced non-small cell lung cancer: incorporation of novel chemotherapeutic agents

Chest
Chandra P Belani, R K Ramanathan

Abstract

The role of multimodality management in locally advanced non-small cell lung cancer (NSCLC) continues to evolve and is a subject of ongoing clinical research. Induction chemotherapy followed by surgical resection with or without thoracic radiotherapy has proved superior to surgical resection alone in patients with ipsilateral mediastinal (N2) disease. Whether surgery alone still plays a role in these patients is the subject of an ongoing intergroup study. As no definitive, optimal effective chemotherapy regimen currently exists for NSCLC, future studies will attempt to incorporate novel and active agents like the taxanes, irinotecan, vinorelbine, and gemcitabine into combined-modality therapy for locally advanced NSCLC. Thoracic radiation therapy by itself provides local control and effective palliation of tumor-related symptoms but has minimal impact on the survival of patients with locally advanced disease. Novel schemes such as hyperfractionated radiotherapy and continuous hyperfractionated accelerated radiotherapy are currently being investigated and appear promising but need to be tested in combination with chemotherapeutic agents. Randomized studies have demonstrated the benefit of concurrent or sequential chemoradiation ...Continue Reading

References

Aug 1, 1979·International Journal of Radiation Oncology, Biology, Physics·E B DoupleM E Tulloh
Feb 20, 1992·The New England Journal of Medicine·C Schaake-KoningA Nijs
Jan 1, 1992·Journal of the National Cancer Institute·T Le ChevalierJ Y Douillard
Jun 1, 1992·The Annals of Thoracic Surgery·H I PassJ Minna
Jan 1, 1992·International Journal of Radiation Oncology, Biology, Physics·M G TrovóC Gobitti
Jan 1, 1992·International Journal of Radiation Oncology, Biology, Physics·M G TrovòC Gobitti
Aug 1, 1991·International Journal of Radiation Oncology, Biology, Physics·M I SaundersA R Makepeace
Sep 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E K RowinskyS E Sartorius
Oct 1, 1991·Clinical Pharmacokinetics·W J van der Vijgh
Dec 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C P BelaniD A Van Echo
Nov 1, 1987·International Journal of Radiation Oncology, Biology, Physics·G van HarskampH M Pinedo
Mar 1, 1988·European Journal of Cancer & Clinical Oncology·K MattsonE Nordman
Apr 1, 1986·International Journal of Radiation Oncology, Biology, Physics·C A PerezR Birch
Mar 1, 1986·International Journal of Radiation Oncology, Biology, Physics·C Schaake-KoningN van Zandwijk
Oct 1, 1987·The Surgical Clinics of North America·N Martini, B J Flehinger
Jan 1, 1983·Journal of Cancer Research and Clinical Oncology·H M PinedoJ B Vermorken
Mar 1, 1982·International Journal of Radiation Oncology, Biology, Physics·E B Douple, R C Richmond
Aug 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C J LangerR F Ozols
Jun 1, 1995·Seminars in Oncology·H Choy, M J Browne
Feb 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B JeremicL Djuric
Apr 13, 1995·The New England Journal of Medicine·E K Rowinsky, R C Donehower
Jan 1, 1994·Pharmacotherapy·D R Kohler, B R Goldspiel
Dec 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H ChoyL Leone
Jan 1, 1995·Cancer·W D TravisS S Devesa
Aug 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K KubotaK Matsui
Mar 3, 1993·Journal of the National Cancer Institute·W K MurphyM N Raber
Jan 1, 1993·Journal of Cancer Research and Clinical Oncology·E K RowinskyR C Donehower
Oct 20, 1993·International Journal of Radiation Oncology, Biology, Physics·M PalazziG Ravasi
Feb 1, 1994·American Journal of Clinical Oncology·S DarwishR Vitali
Jan 1, 1996·CA: a Cancer Journal for Clinicians·S L ParkerP A Wingo
Apr 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B JeremicS Milisavljevic

❮ Previous
Next ❯

Citations

Sep 4, 1999·The Annals of Thoracic Surgery·J R SonettZ Gamliel
Mar 15, 2001·Critical Reviews in Oncology/hematology·H Choy
Jul 17, 1999·Current Opinion in Pulmonary Medicine
Jul 17, 1999·Current Opinion in Pulmonary Medicine·T A Hensing, M A Socinski
Mar 10, 2004·Hematology/oncology Clinics of North America·Yuhchyau Chen, Paul Okunieff
Mar 14, 2002·Expert Opinion on Biological Therapy·Michael L Salgaller
Jul 17, 1999·Current Opinion in Pulmonary Medicine·G A Lillington

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.